Shares of Advaxis Inc. (NASDAQ:ADXS) were up 5.9% during trading on Wednesday . The company traded as high as $8.91 and last traded at $8.56, with a volume of 1,161,444 shares changing hands. The stock had previously closed at $8.08.

A number of analysts recently commented on ADXS shares. FBR & Co reaffirmed an “outperform” rating on shares of Advaxis in a research note on Wednesday, March 9th. HC Wainwright reaffirmed a “buy” rating on shares of Advaxis in a research note on Thursday, April 21st. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a research note on Friday, June 10th. Six investment analysts have rated the stock with a buy rating, Advaxis presently has a consensus rating of “Buy” and an average target price of $24.80.

The firm’s market cap is $298.12 million. The stock has a 50 day moving average price of $8.42 and a 200 day moving average price of $8.19.

In other news, CEO Daniel O’connor sold 8,237 shares of the business’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $7.51, for a total value of $61,859.87. Following the sale, the chief executive officer now owns 316,661 shares of the company’s stock, valued at approximately $2,378,124.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas J. Mckearn sold 4,100 shares of the business’s stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total value of $30,545.00. Following the completion of the sale, the director now directly owns 82,120 shares in the company, valued at approximately $611,794. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Advaxis stock. Oxford Asset Management acquired a new position in Advaxis Inc. (NASDAQ:ADXS) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 146,282 shares of the biotechnology company’s stock, valued at approximately $1,502,000. Oxford Asset Management owned approximately 0.43% of Advaxis as of its most recent filing with the SEC.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.